Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.

Yamaguchi A, Hirata S, Kubo S, Fukuyo S, Hanami K, Nakano K, Nakayamada S, Saito K, Tanaka Y.

Mod Rheumatol. 2019 Dec 7:1-23. doi: 10.1080/14397595.2019.1702141. [Epub ahead of print]

PMID:
31814496
2.

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.

Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y.

Arthritis Res Ther. 2019 Jun 22;21(1):151. doi: 10.1186/s13075-019-1933-8.

3.

Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.

Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Inoue Y, Ueno M, Tanaka Y.

Int J Rheum Dis. 2019 Mar;22(3):434-442. doi: 10.1111/1756-185X.13387. Epub 2018 Oct 18.

PMID:
30338639
4.

IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion.

Nagayasu A, Kubo S, Nakano K, Nakayamada S, Iwata S, Miyagawa I, Fukuyo S, Saito K, Tanaka Y.

Intern Med. 2018 Aug 1;57(15):2251-2257. doi: 10.2169/internalmedicine.0387-17. Epub 2018 Mar 9.

5.

Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.

Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):562-570. Epub 2017 Apr 27.

PMID:
28516880
6.

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.

Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, Saito K, Tanaka Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):834-841. Epub 2016 Aug 31.

PMID:
27607196
7.

Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab.

Nawata M, Saito K, Fukuyo S, Hirata S, Tanaka Y.

Mod Rheumatol. 2016 Nov;26(6):807-812. doi: 10.3109/14397595.2016.1158386. Epub 2016 Apr 26.

PMID:
26915532
8.

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.

Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y.

Mod Rheumatol. 2016 Nov;26(6):850-856. doi: 10.3109/14397595.2016.1153449. Epub 2016 Mar 30.

PMID:
26873570
9.

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.

Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y.

Ann Rheum Dis. 2016 Jul;75(7):1321-7. doi: 10.1136/annrheumdis-2015-207784. Epub 2015 Aug 5.

PMID:
26245754
10.

[Mesenchymal stem cells for the treatment and repair of inflammatory arthritis].

Tanaka Y, Sonomoto K, Kondo M, Oshita K, Zhang XM, Fukuyo S, Yamaoka K.

Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(2):86-92. doi: 10.2177/jsci.38.86. Review. Japanese.

11.

Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats.

Zhang X, Yamaoka K, Sonomoto K, Kaneko H, Satake M, Yamamoto Y, Kondo M, Zhao J, Miyagawa I, Yamagata K, Fukuyo S, Okada Y, Tanaka Y.

PLoS One. 2014 Dec 4;9(12):e114621. doi: 10.1371/journal.pone.0114621. eCollection 2014.

12.

Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.

Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang SP, Yoshikawa M, Saito K, Tanaka Y.

Arthritis Rheumatol. 2015 Jan;67(1):63-73. doi: 10.1002/art.38895.

13.

IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent.

Fukuyo S, Yamaoka K, Sonomoto K, Oshita K, Okada Y, Saito K, Yoshida Y, Kanazawa T, Minami Y, Tanaka Y.

Rheumatology (Oxford). 2014 Jul;53(7):1282-90. doi: 10.1093/rheumatology/ket496. Epub 2014 Mar 4.

PMID:
24599911
14.

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y.

Rheumatology (Oxford). 2014 May;53(5):914-8. doi: 10.1093/rheumatology/ket466. Epub 2014 Jan 17.

PMID:
24441153
15.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.

Ann Rheum Dis. 2015 Feb;74(2):389-95. doi: 10.1136/annrheumdis-2013-204016. Epub 2013 Nov 28. Erratum in: Ann Rheum Dis. 2016 Jul;75(7):e46.

16.

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.

Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Arthritis Res Ther. 2013 Sep 25;15(5):R135. doi: 10.1186/ar4315.

17.

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.

Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Y, Tanaka Y.

Mod Rheumatol. 2014 Jan;24(1):42-51. doi: 10.3109/14397595.2013.854051.

PMID:
24261758
18.

IL-17 inhibits chondrogenic differentiation of human mesenchymal stem cells.

Kondo M, Yamaoka K, Sonomoto K, Fukuyo S, Oshita K, Okada Y, Tanaka Y.

PLoS One. 2013 Nov 15;8(11):e79463. doi: 10.1371/journal.pone.0079463. eCollection 2013.

19.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
20.

Efficacy and safety of reducing duration of infliximab infusion.

Fukuyo S, Saito K, Yamaoka K, Sawamukai N, Hirata S, Nawata M, Iwata S, Tanaka Y.

Mod Rheumatol. 2014 Mar;24(2):275-80. doi: 10.3109/14397595.2013.843747. Epub 2013 Oct 11.

PMID:
24251990
21.

[Orthodontic reconstruction with autotransplantation and bone grafting after a traffic accident].

Mimura H, Fukuyo S.

Orthod Fr. 2013 Jun;84(2):191-200. doi: 10.1051/orthodfr/2013050. Epub 2013 May 30. French.

PMID:
23719247
22.

Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway.

Sonomoto K, Yamaoka K, Oshita K, Fukuyo S, Zhang X, Nakano K, Okada Y, Tanaka Y.

Arthritis Rheum. 2012 Oct;64(10):3355-63. doi: 10.1002/art.34555.

23.

Orthodontic reconstruction with autotransplantation and bone grafting after a traffic accident.

Mimura H, Fukuyo S.

Am J Orthod Dentofacial Orthop. 2012 Apr;141(4 Suppl):S119-29. doi: 10.1016/j.ajodo.2010.09.034.

PMID:
22449592
24.

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.

Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H.

Rheumatology (Oxford). 2011 Oct;50(10):1908-15. doi: 10.1093/rheumatology/ker221. Epub 2011 Jul 13.

25.

Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production.

Oshita K, Yamaoka K, Udagawa N, Fukuyo S, Sonomoto K, Maeshima K, Kurihara R, Nakano K, Saito K, Okada Y, Chiba K, Tanaka Y.

Arthritis Rheum. 2011 Jun;63(6):1658-67. doi: 10.1002/art.30309.

26.

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y.

J Rheumatol. 2011 Apr;38(4):633-41. doi: 10.3899/jrheum.100729. Epub 2010 Dec 15.

PMID:
21159836
27.

Element solubility from dental implants.

Murakami H, Kamiya M, Fukuyo S, Hashimoto K, Horasawa N, Ito M, Takahashi S.

Dent Mater J. 1986 Dec;5(2):172-7. No abstract available.

28.

[Blade implant with shape memory].

Fukuyo S, Yanagisawa S.

DE J Dent Eng. 1984 Autumn;(71):8-9. Japanese. No abstract available.

PMID:
6443084
30.

[Influence of various drugs on liver glycogen and blood sugar levels in reserpinized rats. Combined effect of MAOI, 5HTP, DOPA, ACTH and cortisone].

Kobayashi M, Nino T, Mori T, Fukuyo S, Yazawa T.

Nihon Yakurigaku Zasshi. 1971;67(3):265-73. Japanese. No abstract available.

PMID:
4326925

Supplemental Content

Loading ...
Support Center